Short Communication

The effects of discontinuing cinacalcet at the time of kidney transplantation

Michel Jadoul¹, Ana Baños², Valter J. Zani³ and Gavril Hercz⁴

¹Cliniques Universitaires St Luc, Université Catholique de Louvain, Brussels, Belgium, ²Amgen Ltd, Uxbridge, UK, ³Amgen GmbH, Zug, Switzerland and ⁴Humber River Regional Hospital, Toronto, Canada

Correspondence and offprint requests to: Michel Jadoul; E-mail: michel.jadoul@uclouvain.be

Abstract

Background. The calcimimetic, cinacalcet, is approved for treating secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on dialysis. Biochemical profiles and clinical outcomes in patients discontinuing cinacalcet at kidney transplantation have not been previously described.

Methods. We performed a retrospective observational study evaluating post-transplant biochemical profiles and clinical outcomes in patients who had enrolled in phase 2 or 3 randomized, placebo-controlled studies of cinacalcet before receiving a kidney transplant.

Results. The study included 28 former cinacalcet and 10 former placebo patients. Post-kidney transplant, there were no obvious differences between the two groups in levels of serum intact parathyroid hormone, calcium or phosphorus. One patient in each group underwent post-transplant parathyroidectomy. Kidney transplant failure was apparent in one former cinacalcet-treated patient (4%) and three former placebo patients (30%). The duration of hospitalization (mean ± standard error) immediately post-transplant in these two groups was 2.3 ± 0.3 and 3.4 ± 0.8 weeks, respectively.

Conclusions. Using cinacalcet to treat SHPT in patients with CKD awaiting kidney transplantation does not appear to modify SHPT-related post-transplant biochemical profiles, or clinical outcomes, compared with placebo.

Keywords: cinacalcet; end-stage renal disease; kidney transplantation; secondary hyperparathyroidism

Introduction

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). The calcimimetic, cinacalcet, is approved for treating SHPT in CKD patients receiving dialysis. Randomized, double-blind, placebo-controlled clinical trials in dialyzed patients with SHPT have shown cinacalcet to lower serum parathyroid hormone (PTH), phosphorus, calcium and the calcium–phosphorus product (Ca × P) [1–4]. Cinacalcet facilitates achievement of the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI™) recommended targets for serum PTH, phosphorus, calcium and Ca × P [4,5].

Patients undergoing kidney transplantation may have received cinacalcet before the procedure. However, the biochemical profile of patients who discontinue cinacalcet at the time of their transplant has not been previously described. We report a retrospective, observational study evaluating post-transplant biochemical profiles and clinical outcomes in such patients.

Subjects and methods

Patients

Patients were included in this study if they had withdrawn from a qualifying phase 2 or 3 Amgen-sponsored cinacalcet study to receive a kidney transplant. All patients signed an informed consent form.

Study design

This was an observational, retrospective study. No interventional procedures were undertaken. Patients did not receive cinacalcet after kidney transplantation; if they had been treated with cinacalcet during the qualifying study, the drug was withdrawn when patients left the qualifying study.

Data collection

Local laboratory data relating to serum PTH, calcium and phosphorus levels were collected when patients left the qualifying study, before kidney transplantation and up to 12 months afterwards. Only serum intact (i)PTH measurements were included in this analysis. Information related to the incidences of parathyroidectomy and kidney
transplant failure, duration of post-transplant hospitalization and post-transplant creatinine clearance was also recorded.

Statistical methods

The sample size was determined by the number of patients participating in a qualifying study, withdrawing before kidney transplantation and consenting to follow-up. Data were analysed using descriptive statistics. Between-group comparisons were performed using the chi-square test (categorical variables) and Student’s t-test or the Mann–Whitney test (continuous variables). \( P < 0.05 \) was considered statistically significant.

Results

Patients

Of 107 eligible patients (68 cinacalcet and 39 placebo), 38 (36%) (28 former cinacalcet, 10 former placebo) consented to follow-up, the demographic characteristics of whom were broadly representative of the overall eligible patient population (data not shown). The demographic and baseline biochemical characteristics of the study population are shown in Tables 1 and 2. The mean values for iPTH, phosphorus and calcium levels on entry to the qualifying study among patients consenting to the follow-up were similar to those of the overall eligible patient population (data not shown).

Evaluation of post-transplant biochemical parameters and clinical outcomes

Consistently measured iPTH data were available for only 7/28 former cinacalcet patients; The mean ± standard error (SE) serum iPTH values at the qualifying-study baseline, kidney transplant and 1, 6 and 12 months after transplantation were 881 ± 160 (\( n = 7 \)), 568 ± 325 (\( n = 7 \)), 557 ± 243 (\( n = 7 \)), 481 ± 205 (\( n = 7 \)) and 880 ± 588 (\( n = 5 \)) pg/ml, respectively (93 ± 17, 60 ± 34, 59 ± 26, 51 ± 22 93 ± 62 pmol/l, respectively). The corresponding median (\( Q_1, Q_3 \)) values were 970 (399, 1249), 226 (136, 712), 229 (173, 1175), 322 (156, 528) and 393 (191, 471) pg/ml, respectively. No regular iPTH measurements were available for former placebo patients. Twelve months post-transplant, based on all patients who had available data at this time point, the mean ± SE iPTH values for the former cinacalcet (\( n = 7 \)) and former placebo (\( n = 5 \)) groups were 769 ± 415 pg/ml (82 ± 44 pmol/l) and 674 ± 301 pg/ml (72 ± 32 pmol/l), respectively. The mean value in former cinacalcet patients was heavily influenced by one patient with a very high iPTH concentration (3219 pg/ml); this patient had very high iPTH levels throughout the study (712 pg/ml, 1750 pg/ml, 1663 pg/ml at the qualifying-study baseline and 1 and 6 months after transplantation). The transplant failed in this patient; creatinine clearance was only recorded at Week 1. Excluding this patient, the mean ± SE iPTH value was 361 ± 86 pg/ml (38 ± 9.2 pmol/l) at Month 12. The median (\( Q_1, Q_3 \)) values at Month 12 for the former cinacalcet and placebo patients were 393 (191, 706) and 245 (159, 1302) pg/ml, respectively (Table 2). Median iPTH values at other time points, for both former cinacalcet and former placebo patients for whom data were available, are presented in Table 2. Despite the small number of patients evaluated and the variability of the data, there did not appear to be any obvious difference between the two patient groups. One former cinacalcet patient (4%) and one former placebo patient (10%) underwent post-transplant parathyroidectomy.

In both groups, mean total calcium levels remained similar and relatively unchanged (Table 2) and mean plasma phosphorus concentrations decreased during the first month post-transplant, but remained relatively unchanged thereafter (Table 2).

Kidney transplant failure was apparent in one former cinacalcet-treated patient (4%) and three former placebo patients (30%); the mean ± SE duration of hospitalization immediately post-transplant in these two groups was...
Table 2. Biochemical parameters before and after kidney transplantation in patients who had received either cinacalcet or placebo prior to the transplant and consented to follow-up

|                      | On entry to the qualifying study | At the end of the qualifying study and before kidney transplant | 1 month post-transplant | 6 months post-transplant | 12 months post-transplant |
|----------------------|---------------------------------|---------------------------------------------------------------|------------------------|--------------------------|--------------------------|
|                      | Former placebo patients         | Former cinacalcet patients                                   | Former placebo patients | Former cinacalcet patients | Former placebo patients  |
|                      | Former placebo patients         | Former cinacalcet patients                                   | Former placebo patients | Former cinacalcet patients | Former placebo patients  |
|                      | (n = 10)                        | (n = 28)                                                      | (n = 10)               | (n = 28)                  | (n = 10)                 |
| iPTH (pg/ml)         | 552 [413, 960]                  | 607 [484, 925]                                               | 542 [424, 785]         | 225 [131, 611]            | 221 [221, 221]           |
|                      | 676 ± 114                       | 701 ± 57                                                     | 876 ± 241              | 415 ± 105                 | 221 [n = 1]              |
| Calcium (mg/dl)      | 9.6 ± 0.2                       | 9.8 ± 0.1                                                    | 9.6 ± 0.3              | 9.5 ± 0.2                 | 9.9 ± 0.3                |
|                      | (n = 10)                        | (n = 28)                                                      | (n = 8)                | (n = 23)                  | (n = 9)                  |
| Phosphorus (mg/dl)   | 6.2 ± 0.6                       | 6.4 ± 0.3                                                    | 6.9 ± 0.8              | 5.2 ± 0.3                 | 2.4 ± 0.3                |
|                      | (n = 10)                        | (n = 28)                                                      | (n = 10)               | (n = 27)                  | (n = 10)                 |

Data are missing for some patients.

iPTH = intact parathyroid hormone.

For iPTH, median [Q1, Q3], mean ± standard error values, and the number of patients on whom data are based, are shown. For calcium and phosphorus, mean ± standard error values are shown, together with the number of patients on whom the data are based.
2.3 ± 0.3 and 3.4 ± 0.8 weeks, respectively; mean values for creatinine clearance appeared consistently higher in former cinacalcet patients than former placebo (Figure 1). These differences were not statistically significant.

Discussion

The results from this study suggest that using cinacalcet to treat SHPT in patients with CKD awaiting kidney transplantation does not appear to modify SHPT-related post-transplant biochemical profiles compared with placebo. Limited data also suggest that cinacalcet does not appear to modify post-transplant clinical outcomes. In addition, former cinacalcet-treated patients did not appear to show large post-transplant changes in iPTH in our study—it is important that cinacalcet does not adversely impact on the post-transplant outcome of resistant hyperparathyroidism. However, our findings should be interpreted with caution because of the small sample size, within-group variability of the biochemical parameters we described and the possibility of bias. Its retrospective design made this study susceptible to population bias, but patients recruited were broadly representative of the overall eligible patient population from which they had been drawn. There was no patient selection bias within participating centres—all eligible patients were invited to enrol. However, measurement bias was a possibility—patients for whom no iPTH measurements were obtained may have had less severe SHPT, in which case an effect of cinacalcet may have been missed. Finally, the iPTH assays were measured at local laboratories and consequently there may have been some differences between assays that were not taken into account.

Although kidney transplantation can correct some abnormalities that result in SHPT and studies of early post-transplant changes [7,8] show that PTH levels may decrease, PTH may not completely normalize and data obtained 12 months post-transplant show that hyperparathyroidism may not have resolved [7]. Indeed, observational research examining post-transplant parameters has shown persistent hyperparathyroidism in ∼17% of patients [9]. Patients with moderate-to-severe SHPT before kidney transplant had a higher rate of persistent hyperparathyroidism (~30%) and an incidence of hypercalcaemia of ~50% during the first year post-transplant [9]. In several small studies of up to 6-month duration, cinacalcet controlled persistent hyperparathyroidism in kidney transplant recipients, significantly reducing serum calcium and PTH levels [10–18]. These studies indicate that cinacalcet is a promising therapeutic option for kidney transplant patients with persistent hyperparathyroidism, and a potential alternative to parathyroidectomy. Additional research is warranted to determine whether cinacalcet treatment should be withdrawn or continued in the peri- and post-transplant periods in patients with severe SHPT during dialysis.

Acknowledgements. This study was sponsored by Amgen Inc. We would like to thank Andrew Lockley of Bioscript Stirling for providing writing assistance.

Conflict of interest statement. Michel Jadoul has received honoraria and research grant funding, unrelated to the topic of this study, from Amgen. Ana Baños and Valter Zani are employees of Amgen. Gavril Hercz has no conflicts of interest to declare.

References

1. Block GA, Martin KJ, de Francisco ALM et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med* 2004; 350: 1516–1525
2. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. *J Am Soc Nephrol* 2005; 16: 800–807
3. Sterrett JR, Strom J, Stummvoll HK et al. Cinacalcet HCl (Sensi-par/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. *Clin Nephrol* 2007; 68: 10–17
4. Messa P, Macário F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. *Clin J Am Soc Nephrol* 2008; 3: 36–45
5. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl. *Kidney Int* 2005; 67: 760–771
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31–41
7. Saha HH, Salmela KT, Ahonen P et al. Sequential changes in vitamin D and calcium metabolism after successful renal transplantation. *Scand J Urol Nephrol* 1994; 28: 21–27
8. Alsina J, Gonzalez MT, Bonnin R et al. Long-term evolution of renal osteodystrophy after renal transplantation. *Transplant Proc* 1989; 21: 2151–2158

9. Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. *Nephrol Dial Transplant* 2004; 19: 1281–1287

10. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. *Nephrol Dial Transplant* 2007; 22: 577–583

11. Serra AL, Schwarz AA, Wick FH et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. *Nephrol Dial Transplant* 2005; 20: 1315–1319

12. Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. *Am J Transplant* 2006; 6: 2391–2395

13. Kruse AE, Eisenberger U, Frey FJ et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. *Nephrol Dial Transplant* 2005; 20: 1311–1314

14. Apostolou T, Damianou L, Kotsiev V et al. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. *Clin Nephrol* 2006; 65: 374–377

15. Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. *Transplantation* 2006; 82: 675–680

16. Apostolou T, Kollia K, Damianou L et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. *Transplant Proc* 2006; 38: 3514–3516

17. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. *Clin J Am Soc Nephrol* 2006; 1: 323–326

18. El-Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. *Transplantation* 2007; 83: 546–549

Received for publication: 7.11.08; Accepted in revised form: 26.10.09